Navigation Links
Exiqon Announces Achievement of Primary Milestones in RNAi Project for Tacere Therapeutics
Date:9/18/2009

Exiqon A/S (NASDAQ OMX Copenhagen: "EXQ") today announced the successful completion of several key milestones in a custom-designed RNAi project for Tacere Therapeutics.

San Jose and Copenhagen (PRWEB) September 18, 2009 -- Exiqon A/S (NASDAQ OMX Copenhagen: "EXQ") today announced the successful completion of several key milestones in a custom-designed RNAi project for Tacere Therapeutics. This project resulted from a collaboration between Tacere and Pfizer Inc. to develop and commercialize the TT-033 family of compounds to provide a potential single-administration treatment for the Hepatitis C virus (HCV).

Exiqon was selected to complete a series of customized assays, aimed at the detection of therapeutic shRNA molecules currently under development by Pfizer and Tacere, using Exiqon's proprietary LNA™ technology platform. The assays will be used to assess critical performance points for the RNAi therapeutic in a pre-clinical setting.

"The ability to quantify the levels and assess the biodistribution of therapeutic RNAi are critical issues for those in the field who are developing the technology as a new therapeutic modality," says David Suhy, PhD, Director of Research & Development for Tacere. "Unfortunately, the use of traditional quantitative assays to obtain these data has been hampered by the exceptionally small size of the RNA. The combination of the unique properties of LNA-enhanced oligonucleotides and the demonstrated scientific expertise of the Exiqon team made them an attractive partner for this project."

The nature of the specimens posed a significant challenge for this kind of assay, according to members of the Exiqon development team. "Unlike many detection assays of this kind, which are designed for use within a single cell type per experiment (e.g. cell-pellet assays), this project required the use of animal tissue specimens, which adds a layer of complexity, due to the presence of heterogeneous cellular populations within tissues," says Adam Baker, Director of Diagnostic Product Development for Exiqon. "In addition, these assays were designed and developed for use in Formalin-fixed, Paraffin-embedded (FFPE) tissue samples." FFPE sample preparation, which is an important preservation method used mainly in medical histology, provides several key benefits to researchers and clinicians. FFPE specimens may be stored indefinitely at room temperature, enabling their use in certain diagnostic applications, even decades after fixation. Formalin, however, which is used to fix the tissue, causes cross-linkage between nucleic acids and proteins, leading to RNA modification and degradation, which can impede the development of nucleic acid detection assays in these specimens.

The development of these customized assays represents a new breakthrough in the detection and quantification of RNAi species in tissue samples, according to Exiqon Chief Commercial Officer Erik Holmlin. "Until now, researchers have had to choose, within any particular tissue sample, whether to determine how much of their target is present, or where it has been localized in the tissue," Holmlin explains. "Through the application of LNA™ technology in this novel approach to assay design, we are able to deliver both pieces of information on the same tissue sample, adding a new depth of perspective into the biology taking place. We believe this has the potential to dramatically improve the quality of information obtained from these types of experiments, and reduce development times for new therapies."

Financial terms of the project were not disclosed.

About Exiqon
Exiqon is a biotech company with activities in three business areas where the company's technologies provide a competitive advantage: Sale of diagnostic tests (Exiqon Diagnostics), sale of innovative research products for miRNA research (Exiqon Life Sciences), and in contract research together with pharmaceutical companies (Exiqon Pharma Services). Exiqon is dedicated to personalizing the treatment selection for cancer patients. The aim is to optimize the use of existing medicine and avoid unnecessary and non-effective treatment. By using molecular diagnostic tests that analyze the genetic profile of each patient's tumor, treatment selection can be optimized for individuals. Exiqon is uniquely positioned to develop such new diagnostic tests. Exiqon already markets diagnostic tests that based on fresh tumor tissue enable doctors to test whether their patients are resistant to one or more of the chemotherapies offered to treat these patients and help them select an efficacious treatment. Exiqon's new molecular diagnostic products are based on the LNA™ technology that enables testing on fixed tissue. Launch of the first molecular diagnostic product was announced in December 2008. A number of new products will follow in the years ahead. Using the LNA™ technology is what has allowed Exiqon to establish a position for itself as one of the market's leading providers of research products for gene expression analysis. These research products are used by university scientists and in the pharmaceutical industry around the world to make groundbreaking discoveries about the correlation between gene activity and the development various diseases. Exiqon is also collaborating with pharmaceutical companies in their effort to develop new medicines based on biomarkers (Personalized Medicine). Exiqon has more than 170 employees and is listed on the NASDAQ OMX in Copenhagen. Exiqon is financed until expected breakeven in 2011.

About Tacere Therapeutics
Tacere is an innovative biotechnology company focused on developing therapeutics to treat serious infectious diseases using its proprietary knowledge in the development of RNAi therapeutics. Tacere is located in San Jose, California, USA and its lead therapeutic compounds are RNAi drugs for the treatment of Hepatitis C. For additional information, please visit www.tacerebio.com.

Disclaimer
Forward-looking statements:
This announcement contains forward-looking statements regarding Exiqon's potential future development and financial performance and other statements which are not historical facts. Such statements are made on the basis of assumptions and expectations which, to the best of Exiqon's knowledge, are reasonable and well-founded at this time, but which may prove to be erroneous. Exiqon's operations are characterized by the fact that its actual results may deviate significantly from that described herein as anticipated, believed, estimated or expected.

###

Read the full story at http://www.prweb.com/releases/Exiqon/Tacere_Therapeutics/prweb2900554.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Exiqon Announces 2009 North American Grant Award Winners
2. Exiqon Announces New Grant Program for MicroRNA Research
3. 4 Stair Lifts Announces Grand Opening of Online Store
4. SXC Health Solutions announces pricing of upsized public offering of common shares
5. VIVUS Announces Pricing of Public Offering of Common Stock
6. Medical Malpractice Victim Helps Uphold Constitutional Rights of Patients in Washington State Supreme Court Decision, Perey Law Announces
7. Hill-Rom Announces CEO Succession Plan
8. PRO-DEX, INC. Announces Fiscal 2009 Fourth Quarter and Full-year Results
9. American Pacific Announces Executive Change
10. United Way of Greater Los Angeles Announces Matching Fund Launched by Two Local Philanthropists
11. Satellite Healthcare Announces the Recipients of the 2009 Norman S. Coplon Extramural Grants
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Exiqon Announces Achievement of Primary Milestones in RNAi Project for Tacere Therapeutics
(Date:3/24/2017)... ... , ... “The Adventures of Joey, The Dog Who Barks at Puddles”: a ... to the fullest, as God intended. “The Adventures of Joey, The Dog Who Barks ... pursuing her passion for writing, especially about truth and human behavior. , Published by ...
(Date:3/23/2017)... ... March 23, 2017 , ... The physicians of KSF ... the greater Houston Area. The new location is located at 2255 E. Mossy Oaks ... Springwoods Village. This newest location will provide patients living in the north Houston area ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... Convention Center at 10 North Broadway Avenue, will be an educational and exciting ... practical instruction in the management of chronic pain. , Oklahoma is in a ...
(Date:3/23/2017)... ... March 23, 2017 , ... 82% of adults are unaware of the dangers that infectious ... their teeth the minimum two times a day that dentists recommend. The ramifications of improper ... hours of school and adults missing 164 million hours of work each year due to ...
(Date:3/23/2017)... ... March 23, 2017 , ... Benefits delivery trailblazer, ... app and centralized benefits dashboard solving one of the top frustrations in employee ... For the first time, employees can access up-to-date information and account balances for ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... March 23, 2017 Newborns are highly ... most vaccines because their young immune systems typically ... Children,s Hospital report achieving strong vaccine responses in ... model before human trials — by adding compounds ... In two simultaneous papers, they also describe improved ...
(Date:3/23/2017)... 2017  The goal of the pilot is ... track prescription drugs as they are distributed in ... requirements from US FDA to better protect consumers by ... Blockchain startup Chronicled, which links the ... blockchain technology and recently raised $6.25M, and the LinkLab, ...
(Date:3/23/2017)... , March 23, 2017 /PRNewswire/ - INVICTUS MD STRATEGIES ... FRA: 8IS) Invictus MD announces that AB Laboratories Inc. ... its licensed production facility under the Access to Cannabis ... Hamilton, Ontario . The facility, ... October 2016, is currently operating at half capacity, with ...
Breaking Medicine Technology: